Get the Stockscreener App
2.07
0.24%
0.005
Pre-market:
2.04
-0.03
-1.45%
Soligenix Inc stock is traded at $2.07, with a volume of 21,838.
It is up +0.24% in the last 24 hours and down -13.39% over the past month.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
See More
Previous Close:
$2.065
Open:
$2.08
24h Volume:
21,838
Relative Volume:
0.26
Market Cap:
$6.50M
Revenue:
$960.60K
Net Income/Loss:
$-7.10M
P/E Ratio:
-0.2738
EPS:
-7.56
Net Cash Flow:
$-8.00M
1W Performance:
+0.49%
1M Performance:
-13.39%
6M Performance:
-42.18%
1Y Performance:
-67.66%
1-Day Range:
$2.0297
$2.10
1-Week Range:
$1.97
$2.11
52-Week Range:
$1.68
$14.83
Soligenix Inc Stock (SNGX) Company Profile
Name
Soligenix Inc
Sector
Industry
Phone
609-538-8200
Address
29 EMMONS DRIVE, PRINCETON
Compare SNGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
2.07 | 6.50M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.42 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.85 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.65 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.97 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.13 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-20 | Downgrade | Dawson James | Buy → Neutral |
| Jan-31-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-14-17 | Reiterated | Maxim Group | Buy |
| Jul-17-17 | Initiated | H.C. Wainwright | Buy |
Soligenix Inc Stock (SNGX) Latest News
Soligenix (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat - The Globe and Mail
Soligenix (NASDAQ: SNGX) Announces Positive Data, Continued Advancement of HyBryte(TM) - The Globe and Mail
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ f - GuruFocus
SNGX: Updated IIS Data Shows 75% Response Rate and Three Complete Responses… - MSN
Soligenix Announces Positive Data For Extended HyBryte In Early-stage Cutaneous T-cell Lymphoma - Nasdaq
Soligenix (SNGX) Reports Promising Interim Results for HyBryte i - GuruFocus
Positive Outcome in 75% of CTCL Patients Treated with HyBrytetm for 18 Weeks - Lelezard
Soligenix IncPositive Outcome In 75% Of Ctcl Patients Treated With Hybryte For 18 Weeks - marketscreener.com
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks - Finansavisen
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks (PR Newswire) - Aktiellt
Behcet's Disease Market to Show Remarkable Growth Trends from - openPR.com
Behcet’s Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Soligenix, Chugai Pharma, UMC Utrecht, Ganzhou Hemay Pharma, Amgen - The Globe and Mail
Soligenix (NASDAQ: SNGX) Spotlighted In Zacks Small-Cap Research Report, Earns $35 Valuation - Barchart.com
Soligenix (NASDAQ: SNGX) Spotlighted in Zacks Small-Cap Research Report, Earns $35 Valuation - The Globe and Mail
SNGX stock touches 52-week low at $1.74 amid market challenges - Investing.com Canada
SNGX stock touches 52-week low at $1.74 amid market challenges By Investing.com - Investing.com South Africa
Soligenix (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment - Barchart.com
Zacks Small Cap Decreases Earnings Estimates for Soligenix - The AM Reporter
Zacks Maintains $35.00 Price Per Share Valuation for Soligenix (NASDAQ: SNGX) Amid Promising Vaccine and CTCL Therapy Progress - Barchart.com
Q1 Earnings Forecast for Soligenix Issued By Zacks Small Cap - Defense World
SNGX: Preclinical Data Shows CiVax™ Booster Induces Broad Protection Against COVID-19… - Yahoo Finance
CiVax booster shows broad COVID-19 variant protection By Investing.com - Investing.com South Africa
IBN Initiates Coverage of Soligenix Inc. - GlobeNewswire
First National Financial Corporation to Host First Quarter Earnings Call on April 30, 2025 - The Globe and Mail
CiVax booster shows broad COVID-19 variant protection - Investing.com
Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants - PR Newswire
Soligenix (NASDAQ: SNGX) Announces Key Milestones and 2024 Financial Results - The Globe and Mail
Soligenix Inc. (SNGX) reports earnings - Quartz
SOLIGENIX, INC. SEC 10-K Report - TradingView
Soligenix Trumps Year-End Financials - Baystreet.ca
Soligenix reports progress and 2024 financials By Investing.com - Investing.com Australia
Soligenix reports progress and 2024 financials - Investing.com India
Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results - Quantisnow
Soligenix Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Soligenix Financial Results Reveal Widening Losses While Clinical Pipeline Expands - StockTitan
Why Soligenix (NASDAQ: SNGX) Is ‘One to Watch’ - The Globe and Mail
Soligenix (SNGX) Expected to Announce Earnings on Friday - The AM Reporter
Soligenix Inc expected to post a loss of 95 cents a shareEarnings Preview - TradingView
Soligenix (SNGX) Projected to Post Earnings on Friday - Defense World
Soligenix (NASDAQ: SNGX) Is ‘One to Watch’ - The Globe and Mail
Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’ - Financial Content
AllPennyStocks.com News: A Steady Stream of News and Developments Pushes Soligenix Near 52 Week High - ACCESS Newswire
Soligenix, Inc. (NASDAQ:SNGX) Sees Large Decrease in Short Interest - Defense World
HyBryte™ Treatment Studies Presented at Two Medical Conferences in March - Yahoo Finance
Soligenix (SNGX) Projected to Post Quarterly Earnings on Thursday - Defense World
BiomednewsbreaksSoligenix Inc. (SNGX) To Present Hybrytetm And SGX302 Data At Dermatology Conferences - MENAFN.COM
Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Soligenix Aims To Push The Boundaries In Treating Rare Diseases - The Globe and Mail
Soligenix Inc Stock (SNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
21.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):